<?xml version="1.0" encoding="UTF-8"?>
<p>In the recent weeks, in the countries heavily interested by the COVID-19 outbreak, such as Italy, the scientific associations recommended the prudential postponing of active cancer treatments, especially for stable patients not needing urgent interventions [
 <xref rid="B11" ref-type="bibr">11</xref>]. On one hand, this recommendation could be reasonable for advanced cancer patients receiving chemotherapy, with the risk of hematological toxicity and of worsening an immunosuppressed status, thus favoring COVID-19 morbidity [
 <xref rid="B5" ref-type="bibr">5</xref>]. On the other hand, some oncologists are even currently wondering about the risk of administering ICI in the middle of the COVID-19 outbreak, essentially due to two major concerns.
</p>
